

## **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, or claims in the application.

### **Listing of Claims:**

**Claim 1 (Original):** A chimeric ebola envelope protein comprising a functional ebola glycoprotein binding domain fused to a heterologous amino acid sequence.

**Claim 2 (Original):** The chimeric ebola envelope protein according to claim 1, wherein said protein contains a wild-type ebola glycoprotein binding domain.

**Claim 3 (Original):** The chimeric ebola envelope protein according to claim 1, wherein said heterologous amino acid sequence is an ebola glycoprotein sequence which is non-contiguous with the binding domain in the wild-type ebola.

**Claim 4 (Original):** The chimeric ebola envelope protein according to claim 1, wherein said chimeric protein comprises an ebola signal peptide and an ebola binding domain having a deletion in the native ebola region between the signal peptide and the binding domain.

**Claim 5 (Original):** The chimeric ebola envelope protein according to claim 4, wherein said chimeric protein comprises a deletion of about 1 to 50 amino acids between the signal peptide and the binding domain.

**Claim 6 - 16 (Canceled).**

**Claim 17 (Original):** The chimeric ebola envelope protein according to claim 1, selected from the group consisting of:

(a) NTDL1, amino acids 1 to 366 fused to amino acids 497 to 676 of the ebola glycoprotein, SEQ ID NO:1;

- (b) NTDL2, amino acids 1 to 366 fused to amino acids 502 to 676 of the ebola glycoprotein, SEQ ID NO:1;
- (c) NTDL3, amino acids 1 to 370 fused to amino acids 492 to 676 of the ebola glycoprotein, SEQ ID NO:1;
- (d) NTDL4, amino acids 1 to 311 fused to amino acids 497 to 676 of the ebola glycoprotein, SEQ ID NO:1;
- (e) NTDL5, amino acids 1 to 287 fused to amino acids 497 to 676 of the ebola glycoprotein, SEQ ID NO:1;
- (f) NTDL6, amino acids 1 to 279 fused to amino acids 497 to 676 of the ebola glycoprotein, SEQ ID NO:1;
- (g) NTDL7, amino acids 1 to 267 fused to amino acids 497 to 676 of the ebola glycoprotein, SEQ ID NO:1;
- (h) NTDL8, amino acids 1 to 258 fused to amino acids 497 to 676 of the ebola glycoprotein, SEQ ID NO:1;
- (i) NTDL9, amino acids 1 to 232 fused to amino acids 497 to 676 of the ebola glycoprotein, SEQ ID NO:1;
- (j) NTDL11, amino acids 1 to 231 fused to amino acids 497 to 676 of the ebola glycoprotein, SEQ ID NO:1;
- (k)  $\Delta$ N, amino acids 1 to 31 fused to 172 to 676 of the ebola glycoprotein, SEQ ID NO:1;
- (l) Ebo $\Delta$ 5S, amino acids 1 to 220 of the ebola glycoprotein, SEQ ID NO:2;
- (m) Ebo $\Delta$ 6S, amino acids 1 to 361 of the ebola glycoprotein, SEQ ID NO:2;
- (n) Ebo $\Delta$ 7S, amino acids 1 to 628 of the ebola glycoprotein, SEQ ID NO:2; and
- (o) Ebo $\Delta$ 8S, amino acids 1 to 311 fused to amino acids 497 to 664 of the ebola glycoprotein, SEQ ID NO:2;
- (p) V/TC, amino acids 1 to 672 of SEQ ID NO:1 fused to amino acids 463 to 511 of SEQ ID NO:3;

(q) -2aa, amino acids 1 to 672 of SEQ ID NO:1 fused to amino acids 465 to 511 of SEQ ID NO:3;

(r) +2aa, amino acids 1 to 672 of SEQ ID NO:1 fused to amino acids 461 to 511 of SEQ ID NO:3;

(s) +16aa, amino acids 1 to 672 of SEQ ID NO:1 fused amino acids 447 to 511 of SEQ ID NO:3;

(t) +23aa, amino acids 1 to 672 of SEQ ID NO:1 fused to amino acids 440 to 511 of SEQ ID NO:3;

(u) +42aa, amino acids 1 to 672 of SEQ ID NO:1 fused to amino acids 421 to 511 of SEQ ID NO:3;

(v) V/C, amino acids 1 to 672 of SEQ ID NO:1 fused to amino acids 483 to 511 of SEQ ID NO:3;

(w) V/2C, amino acids 1 to 676 of SEQ ID NO:1 fused to amino acids 483 to 511 of SEQ ID NO:3;

(x) V/T, amino acids 1 to 650 of SEQ ID NO:1 fused to amino acids 463 to 482 of SEQ ID NO:3;

(y) ΔInt, amino acids 1 to 629 of SEQ ID NO:1 fused to amino acids sequences 463 to 511 of SEQ ID NO:3;

(z) ΔImm, amino acids 1 to 563 of SEQ ID NO:1 fused to amino acids 463 to 511 of SEQ ID NO:3;

(aa) VE, amino acids 180 to 350 of SEQ ID NO:1 in the VSV-G envelope, SEQ ID NO:3.

(ab) H/TC, amino acids 1 to 650 of SEQ ID NO:1 fused to amino acids 661 to 856, SEQ ID NO:8;

(ac) M/C, amino acids 1 to 650 of SEQ ID NO:1 fused to a VSV-G transmembrane domain, 465 to 482 of SEQ ID NO:3, and an MLV-GP cytoplasmic domain, amino acids 634 to 649 of SEQ ID NO:6;

(ad) M/CR, amino acids 1 to 650 of SEQ ID NO:1 fused to a VSV-G transmembrane domain, 465 to 482 of SEQ ID NO:3, an MLV-GP cytoplasmic domain, amino acids 634 to 649 of SEQ ID NO:6, and an R peptide of MLV-GP, amino acids 650 to 665 of MLV-GP, SEQ ID NO:6;

(ae) L/TC, amino acids 1 to 650 of SEQ ID NO:1, fused to amino acids 439 to 498 of LCMV-GP, SEQ ID NO:9.

Claims 18 - 48 (Canceled).